CYP2C19 Rapid Metabolizer

If a gene report lists you as a CYP2C19 rapid metabolizer, you probably want to know which of your medicines this affects and what to ask your prescriber. This guide explains the label, the genes behind it and the drugs where it matters most.

Introduction to Metabolizers

Metabolizers play a crucial role in how our bodies process medications. The term “metabolizer” refers to an individual’s genetic capacity to break down and eliminate drugs from their system. Variability in these processes can significantly affect both the efficacy of medications and the risk of adverse effects. Genetic variations, especially in drug-metabolizing enzymes, influence how individuals respond to drugs. Based on these genetic differences, people are generally categorized into five main types of metabolizers: poor, intermediate, extensive (normal), rapid, or ultrarapid.

How Different People React to Drugs

Each person’s reaction to medication can vary widely, leading to differences in effectiveness and safety. Factors such as genetics, age, sex, and overall health contribute to this variability. However, genetic polymorphisms in the genes encoding drug-metabolizing enzymes are key determinants of how drugs are processed in the body. For example, two patients prescribed the same dosage of the same medication may experience vastly different outcomes: one may experience the desired effect, while the other may suffer from side effects or an insufficient therapeutic response.

Introduction to CYP2C19

CYP2C19 is a member of the cytochrome P450 family of enzymes, which are essential for the metabolism of a wide variety of drugs. Variations in the CYP2C19 gene can lead to different metabolizer phenotypes. Those classified as CYP2C19 rapid metabolizers process certain medications more quickly than normal. For drugs that CYP2C19 breaks down, this rapid metabolism can result in reduced drug efficacy, as the medication may be cleared from the body before it has a chance to exert its full therapeutic effect.

Types of Metabolizers

There are five main types of metabolizers based on how efficiently their bodies metabolize medications:

Poor Metabolizers (PM):

Poor metabolizers have genetic variations that result in the reduced or absent activity of certain enzymes, typically those in the cytochrome P450 (CYP450) family, such as CYP2C19 or CYP2D6. These individuals process drugs slowly, leading to higher drug levels in the blood, which can increase the risk of side effects and toxicity. In some cases, poor metabolizers may also experience diminished therapeutic effects with prodrugs that need to be metabolized into their active form.

Example:

A poor metabolizer of CYP2C19 may experience stronger or longer-lasting sedation with standard doses of some benzodiazepines (e.g., diazepam).

Intermediate Metabolizers (IM):

Individuals in this category typically have one normal and one reduced- or no-function allele of the gene encoding the enzyme. Their metabolic capacity is slower than that of normal metabolizers but faster than poor metabolizers. These individuals may experience drug effects similar to poor metabolizers but may be at a lower risk for toxicity.

Extensive Metabolizers (Normal Metabolizers):

Extensive metabolizers, also known as normal metabolizers, process drugs at the expected rates. These individuals have two normal alleles and usually experience the typical therapeutic effects of medications. For most drugs, the standard dose is appropriate for extensive metabolizers.

Example:

A person with normal CYP2C19 activity will likely respond to standard doses of clopidogrel with the desired antiplatelet effect.

Rapid Metabolizers (RM):

Rapid metabolizers process some drugs faster than normal, which can result in reduced drug efficacy as the medication is eliminated from the body faster than expected. These individuals may require higher doses of certain drugs or alternative medications to achieve therapeutic effects. For prodrugs that the enzyme activates, faster metabolism does not reduce the effect.

Example:

A CYP2C19 rapid metabolizer may clear proton pump inhibitors such as omeprazole or lansoprazole faster, which can mean weaker acid control at a standard dose. Clopidogrel is different: it is a prodrug that CYP2C19 activates, so rapid metabolizers are generally expected to respond to standard doses, just like normal metabolizers.

Ultrarapid Metabolizers (UM):

Ultrarapid metabolizers usually carry two increased-function alleles (for CYP2C19, two copies of the *17 allele). Their enzyme activity is higher again than in rapid metabolizers, so lower levels of drugs that the enzyme breaks down are more likely. For CYP2C19, current guidelines still group ultrarapid metabolizers with normal metabolizers for clopidogrel.

Introduction to CYP2C19

CYP2C19 is a key enzyme in the cytochrome P450 family responsible for metabolizing a variety of medications. Variations in the CYP2C19 gene can lead to different metabolizer phenotypes, which can impact how individuals respond to certain drugs. As mentioned earlier, CYP2C19 metabolizes medications involved in psychiatric, cardiovascular, and gastrointestinal conditions, among others.

Diseases and Medications Influenced by CYP2C19

CYP2C19 plays an essential role in the metabolism of several drugs, especially those used to treat depression, cardiovascular disease, and gastrointestinal disorders. For instance:

• Antidepressants: Medications like sertraline and citalopram are metabolized by CYP2C19. Variations in the enzyme may affect how well individuals respond to these drugs.
• Antiplatelet agents: Drugs like clopidogrel are activated by CYP2C19. Poor metabolizers may not convert clopidogrel into its active form, leading to an increased risk of blood clots.
•  Proton pump inhibitors: Drugs like omeprazole and esomeprazole, used to treat GERD and peptic ulcers, are also metabolized by CYP2C19. The enzyme’s activity can affect the drug’s effectiveness in managing gastric acid production.
• Myosin Inhibitor: Drugs like Mavacamten are used as medications to treat obstructive hypertrophic cardiomyopathy (HCM). As CYP2C19 is dominant in metabolising Mavacamten, variations in this enzyme can significantly affect how the drug is processed in the body. CYP2C19 poor metabolizers may experience higher drug concentrations, increasing the risk of adverse effects such as heart failure symptoms, while faster metabolizers may have lower drug levels. This drug’s metabolism is influenced by the CYP2C19 enzyme’s activity, which can vary between individuals. This is why prescribers monitor treatment closely and may consider results from pharmacogenetic testing when choosing a dose. The role of CYP2C19 in Mavacamten metabolism highlights the importance of personalized medicine, especially in conditions like hypertrophic cardiomyopathy, where precise dosing is crucial to manage symptoms and prevent complications.

Do you know?

RPh LABS PGx test reports are easy enough that one can have a basic understanding of their metabolism before even visiting their doctor. And in case of trouble, we have our lab specialists ready to help.

How to Identify Metabolizer Status

To determine an individual’s metabolizer status, pharmacogenetic (PGx) testing can be conducted. This genetic testing looks for specific polymorphisms in the genes encoding drug-metabolizing enzymes like CYP2C19. Based on these findings, healthcare providers can categorize individuals as:

• Poor metabolizers: Process drugs slowly, potentially increasing the risk of side effects.

• Intermediate metabolizers: Have moderately reduced enzyme activity, which may require adjustments to drug dosages.
• Extensive metabolizers: Have normal enzyme activity, responding to standard drug dosages.
• Rapid metabolizers: Process some drugs quickly, possibly leading to reduced drug effectiveness, and may require higher doses of those drugs.
• Ultrarapid metabolizers: Have the highest enzyme activity, so lower levels of drugs the enzyme breaks down are more likely.

Benefits of PGx Testing for CYP2C19 Metabolizers

Pharmacogenetic testing offers personalized medication management, particularly for those with CYP2C19 variations. Benefits include:

• Personalized Treatment: PGx testing helps identify the most effective medications and dosages for each individual based on their metabolizer phenotype. Rapid metabolizers may need higher doses or alternative drugs for some medicines, while poor metabolizers may need reduced dosages or, for prodrugs such as clopidogrel, a different drug.
• Improved Safety: By identifying potential drug interactions or adverse reactions, PGx testing can reduce the risk of harm. For instance, poor metabolizers of clopidogrel may benefit from alternative therapies that don’t rely on CYP2C19 metabolism.
• Enhanced Efficacy: Identifying whether a person is a rapid metabolizer can help adjust treatment plans to ensure that drugs are present in therapeutic concentrations for adequate efficacy.
• Informed Decision Making: Both patients and healthcare providers can make more informed decisions about drug selection and dosing when the metabolizer status is known, leading to better clinical outcomes and fewer trial-and-error adjustments.

Special Considerations for Pregnant Women

Pregnant women may experience changes in drug metabolism due to hormonal fluctuations, particularly during the second and third trimesters. As a result, knowing whether a pregnant woman is a CYP2C19 rapid metabolizer can be important for medication management. PGx testing can help healthcare providers determine the most effective and safe treatment plan for the mother and fetus. Some considerations include:

• Dosage Adjustments: A rapid metabolizer may need higher doses or different medications to ensure therapeutic effectiveness during pregnancy.

• Medication Safety: Identifying poor or rapid metabolism early can reduce the risk of ineffective treatment or adverse outcomes for the mother and fetus.

Added Value – Since we have noticed a high demand for the rapid metabolizer drug list, it has been specifically added for your reference. Please note that these drugs are not specifically for rapid metabolizers only – it’s just that rapid metabolizers may notice reduced effects in case of these medications.

CYP2C19 Rapid Metabolizer Drug List:

Here is the list of common medications metabolized by CYP2C19, with a focus on drugs that are commonly prescribed to rapid metabolizers:

Antidepressants (SSRIs, SNRIs, etc.)

CYP2C19 plays a significant role in metabolizing many selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs).

• Escitalopram (Cipralex, Lexapro)
• Citalopram (Celexa)
• Fluoxetine (Prozac) – less dependent on CYP2C19 than others but still metabolized by it
• Sertraline (Zoloft) – partly metabolized by CYP2C19
• Amitriptyline (Elavil) – TCA (Tricyclic Antidepressant), metabolized by CYP2C19

Effect on Rapid Metabolizers: Rapid metabolizers may require higher doses for efficacy, as the drug will be cleared from the system more quickly. Conversely, slower metabolizers may need lower doses to avoid side effects.

Antipsychotics

Most antipsychotics are processed mainly by other enzymes, so CYP2C19 status has little effect on them. For example, clozapine and olanzapine are processed mainly by CYP1A2, while aripiprazole and risperidone depend mostly on CYP2D6.

Benzodiazepines

Several benzodiazepines are metabolized by CYP2C19. Rapid metabolism may lead to reduced sedative effects or shorter duration of action.

• Diazepam (Valium)
• Clobazam (Onfi) – its active metabolite is broken down by CYP2C19

Effect on Rapid Metabolizers: Rapid metabolizers may not experience the full sedative effect and may require higher doses. Conversely, slower metabolizers may experience prolonged sedation and increased risk of side effects.

Proton Pump Inhibitors (PPIs)

PPIs are often used to treat gastroesophageal reflux disease (GERD) and other stomach acid-related conditions. CYP2C19 plays a role in metabolizing these drugs.

• Omeprazole (Prilosec)
• Esomeprazole (Nexium)
• Lansoprazole (Prevacid)
• Pantoprazole (Protonix)

Effect on Rapid Metabolizers: Rapid metabolizers may not achieve effective acid suppression and might require higher doses of PPIs to manage acid reflux or ulcers.

Antiepileptic Drugs

Some antiepileptic drugs (AEDs) are also metabolized by CYP2C19, and dosing may need adjustment in rapid metabolizers.

• Clobazam (Onfi)
• Phenytoin (Dilantin) – mainly processed by CYP2C9, with a smaller CYP2C19 role

Effect on Rapid Metabolizers: Rapid metabolizers may require higher doses for optimal seizure control because the drugs are cleared from the body more quickly.

Rapid vs CYP2C19 ultrarapid metabolizer: what the labels mean

Labs describe CYP2C19 activity with five standard phenotypes: poor, intermediate, normal, rapid and ultrarapid. The last two are easy to mix up, and some older articles use “rapid” to cover both. Current guidelines from the Clinical Pharmacogenetics Implementation Consortium (CPIC) keep them separate because the drug advice can differ.

A CYP2C19 rapid metabolizer usually carries one normal-function copy of the gene and one increased-function copy. A CYP2C19 ultrarapid metabolizer carries two increased-function copies. Enzyme activity is a little higher in the rapid group and higher again in the ultrarapid group, which is why a CYP2C19 ultrarapid metabolizer is more likely to notice lower drug levels.

In practice, this means a rapid result is a nudge rather than an alarm. For many drugs the standard dose still works. For a smaller group of medicines that depend heavily on CYP2C19, the faster clearance can lower drug levels enough that your prescriber may want to watch your response more closely or pick a different option.

• Normal metabolizer: two normal-function copies, expected drug levels.
• Rapid metabolizer: one normal and one increased-function copy, slightly lower levels of some drugs.
• Ultrarapid metabolizer: two increased-function copies, lower levels of some drugs are more likely.

The CYP2C19 *17 allele explained

Gene versions are named with star alleles. For CYP2C19, *1 is the normal-function reference version, *2 and *3 are the most common no-function versions, and the CYP2C19 *17 allele is the main increased-function version. You can browse the official allele definitions at PharmVar.

The CYP2C19 *17 allele does not change the enzyme itself. It sits in the region that controls how much enzyme your liver makes, so carriers simply produce more of it. That is why *1/*17 is reported as a CYP2C19 rapid metabolizer and *17/*17 as ultrarapid.

Combinations matter too. Someone with *2/*17 has one no-function copy and one increased-function copy. Guidelines currently classify this as an intermediate metabolizer, not a rapid one, because the lost copy has the bigger effect. If your report shows a *17 but a phenotype you did not expect, this is often the reason.

Your genotype does not change over your lifetime, so a single CYP2C19 result stays useful for every future prescription. What can change is how guidelines interpret it, which is one reason to keep a copy of your report and share it with each new prescriber.

Clopidogrel and CYP2C19: where rapid status fits

Clopidogrel (Plavix) is a prodrug. It does nothing until CYP2C19 converts it into its active form, which then keeps platelets from clumping after a heart attack, stent or stroke. That is why clopidogrel and CYP2C19 are one of the best-studied gene and drug pairs.

The main concern runs in the opposite direction from rapid metabolism. Poor and intermediate metabolizers make less of the active drug, so they may get less protection. Current CPIC guidelines suggest prescribers consider an alternative antiplatelet drug for many of these patients.

For a CYP2C19 rapid metabolizer or a CYP2C19 ultrarapid metabolizer, CPIC places clopidogrel in the same group as normal metabolizers: the standard dose is generally expected to work. Rapid status on its own is not a reason to change clopidogrel. The final choice always rests with your cardiologist, who also weighs bleeding risk, other medicines and your heart history.

The FDA table of pharmacogenomic biomarkers lists clopidogrel with a boxed warning about CYP2C19 poor metabolizers, which shows how seriously regulators take the link between clopidogrel and CYP2C19. If you take clopidogrel, a CYP2C19 genetic test is one of the most practical PGx results you can bring to your cardiologist.

What a CYP2C19 rapid metabolizer result means for PPIs and antidepressants

Proton pump inhibitors are the drugs most affected by faster CYP2C19 activity. Omeprazole, lansoprazole and pantoprazole are cleared mostly by this enzyme, so a CYP2C19 rapid metabolizer may have lower drug levels and weaker acid control. CPIC suggests prescribers consider a higher starting dose for certain conditions, such as H. pylori infection and erosive esophagitis, in rapid and ultrarapid metabolizers.

Citalopram and escitalopram are the antidepressants where CYP2C19 matters most. Faster clearance can leave less drug in the body, which may show up as a weak response at a usual dose. Depending on the exact phenotype, guidance ranges from monitoring and adjusting the dose to choosing an antidepressant that relies less on CYP2C19. Our guide to genetic testing for antidepressants covers this in more depth.

Other medicines with CYP2C19 guidance include the antifungal voriconazole and tricyclic antidepressants such as amitriptyline. For these, guidelines suggest prescribers consider alternatives for some rapid and ultrarapid metabolizers. You can see how each drug maps to its genes on our medication list.

How a CYP2C19 genetic test works and what the report shows

A CYP2C19 genetic test looks for the specific DNA variants that define the star alleles, then combines your two alleles into a phenotype. Most tests use a cheek swab or saliva sample. No fasting or blood draw is needed, and it does not matter whether you are taking any medicines at the time.

The RPh Labs at-home PGx kit uses a cheek swab and includes CYP2C19 in a 20-gene panel, along with CYP2D6, CYP2C9, SLCO1B1 and others. Results arrive 7 to 10 business days after the sample reaches our CLIA-certified lab, every report is reviewed by a PharmD pharmacist, and a free pharmacist consultation is included.

A useful report shows three things for CYP2C19, including whether you carry the CYP2C19 *17 allele:

1. Your genotype, for example *1/*17.
2. Your phenotype, for example rapid metabolizer.
3. The medicines where that phenotype has published guidance, with a short note on what the guidance says.

Want to see each step, from swab to report? Read how it works.

Talking to your prescriber about a CYP2C19 rapid metabolizer result

Your result is most helpful when it reaches the people who prescribe for you. Bring the full report, not just the phenotype line, and ask which of your current medicines use CYP2C19. Never stop or change a medicine on your own because of a gene result.

Other drugs can shift your real-world enzyme activity. Fluvoxamine and fluconazole can slow CYP2C19, while rifampin and St. John’s wort can speed it up. So a CYP2C19 rapid metabolizer taking a strong inhibitor may act more like a normal or slower metabolizer. The same applies to clopidogrel and CYP2C19 inhibitors taken together, which your prescriber and pharmacist will want to know about. Tell them about every prescription, supplement and over-the-counter product.

• Which of my medicines have CYP2C19 guidance?
• Does my result change the dose you would start me on?
• Are any of my other medicines changing how CYP2C19 works?
• Can you add this result to my medical record for future prescriptions?

Remember that genes are one input. Age, liver function, other illnesses and adherence all shape how a medicine works for you.

Conclusion

Understanding an individual’s metabolizer status can significantly improve treatment strategies. PGx testing kit empowers healthcare providers to tailor medication choices and doses based on each patient’s unique genetic makeup, which can support better outcomes and reduce trial and error.

References Medline Plus FDA.Gov

This blog contains data only for informational purposes. Always consult a doctor before taking any medical action.

CYP2C19 rapid metabolizer FAQ

What are the CYP2C19 rapid metabolizer symptoms?

Rapid metabolizers of any specific enzyme tend to clear some specific medications faster than others, as the drugs are removed quickly from the system, they experience reduced effectiveness. The cyp2c19 rapid metabolizers show less effectiveness with certain medications, e.g. Omeprazole (Prilosec), which is an FDA-approved proton pump inhibitor, and Amitriptyline (Elavil), which is again an FDA-approved tricyclic antidepressant.

Why is Adderall not affecting me?

Amphetamine, the active ingredient in Adderall, is partly broken down by CYP2D6, and much of it leaves the body unchanged in urine. If you have increased CYP2D6 activity, a normal dose may wear off faster for you, although urine acidity, dose timing and other factors often matter more. A PGx test by RPh LABS may provide you with a clear picture that can be used to get the right medication and the right dosage.

What are PPIs?

PPI is abbreviated as proton pump inhibitors. This drug class typically treats gastroesophageal reflux disease and stomach ulcers. This drug class is also metabolised by CYP2C19; thus, knowing your metabolic reaction to this with the help of a PGx test could be helpful.

What are the side effects of long-term PPI use?

Research has linked long-term PPI use to possible renal (kidney, ureters, and the urethra) problems, cardiovascular disease, fractures (due to more insoluble calcium and decreased calcium absorption), infections, micronutrient deficiencies, hypergastrinemia (occurs due to excess of gastrin), cancers, hepatic encephalopathy, and dementia. Many of these links come from observational studies and have not been proven to be caused by PPIs, so talk to your prescriber before stopping one.

Is being a CYP2C19 rapid metabolizer dangerous?

Usually not. For most medicines the standard dose still works. The main effect is that a few drugs, such as some proton pump inhibitors and escitalopram, may be cleared faster and work less well. Your prescriber can use your result to watch your response or choose a better fit. Never change a medicine on your own.

What is the difference between *1/*17 and *17/*17?

*1/*17 means one normal and one increased-function copy, which is reported as a CYP2C19 rapid metabolizer. *17/*17 means two increased-function copies, which is reported as a CYP2C19 ultrarapid metabolizer. The CYP2C19 *17 allele raises how much enzyme your body makes, so two copies usually means faster clearance of CYP2C19 drugs than one copy.

Does a CYP2C19 ultrarapid metabolizer need a different clopidogrel dose?

Current CPIC guidance groups rapid and ultrarapid metabolizers with normal metabolizers for clopidogrel, so the standard dose is generally expected to work. The main genetic concern with clopidogrel is in poor and intermediate metabolizers, who activate less of the drug. Your cardiologist makes the final decision.

Do I need a CYP2C19 genetic test more than once?

No. Your DNA does not change, so one CYP2C19 genetic test covers your lifetime. What can change is how guidelines interpret a result, so keep your report and share it with every new prescriber and pharmacist. RPh Labs updates reports when guidelines change.

Can other medicines change my CYP2C19 activity?

Yes. Drugs such as fluvoxamine and fluconazole can slow CYP2C19, and rifampin or St. John’s wort can speed it up. This means a CYP2C19 rapid metabolizer can behave differently in real life than the gene result suggests. Share a full medicine and supplement list with your prescriber so they can account for it.

Will insurance pay for CYP2C19 testing?

Coverage varies by plan and by the reason for testing, and a CYP2C19 genetic test is often part of a wider panel. RPh Labs accepts insurance including Medicare, Texas Medicaid and Blue Cross Blue Shield of Texas. The self-pay price for the full 20-gene panel is $299 and is HSA and FSA eligible. See our insurance page for details.